Table 3.
Characteristics of the 322 EGFR/ALK-positive patients.
| Characteristic | SM only (n = 162) | SM+EBR (n = 90) | SM+DBR (n = 38) | SM+BS (n = 27) | BLT only (n = 5) | p-value |
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||
| Age, years Median (range) <65 ≥65 |
53 (26–89) 138 (85.2) 24 (14.8) |
54 (17–78) 79 (87.8) 11 (12.2) |
53 (33–67) 37 (97.4) 1 (2.6) |
61 (29–74) 21 (77.8) 6 (22.2) |
50 (49–70) 4 (80.0) 1 (20.0) |
0.106 |
| Gender Male Female |
70 (43.2) 92 (56.8) |
45 (50.0) 45 (50.0) |
21 (55.3) 17 (44.7) |
10 (37.0) 17 (63.0) |
1 (20.0) 4 (80.0) |
0.345 |
| Smoking status Never Former/current |
125 (77.2) 37 (22.8) |
57 (63.3) 33 (36.7) |
25 (65.8) 13 (34.2) |
24 (88.9) 3 (11.1) |
5 (100.0) 0 (0) |
0.019 |
| Pretreatment KPS >70 ≤70 |
155 (95.7) 7 (4.3) |
88 (97.8) 2 (2.2) |
38 (100.0) 0 (0) |
26 (96.3) 1 (3.7) |
4 (80.0) 1 (20.0) |
0.212 |
| Histology Adenocarcinoma Non-adenocarcinoma |
156 (96.3) 6 (3.7) |
86 (95.6) 4 (4.4) |
37 (97.4) 1 (2.6) |
24 (88.9) 3 (11.1) |
4 (80.0) 1 (20.0) |
0.166 |
| No. of brain metastases 1 2–4 >4 |
48 (29.6) 41 (25.3) 73 (45.1) |
18 (20.0) 16 (17.8) 56 (62.2) |
7 (18.4) 14 (36.8) 17 (44.8) |
14 (51.9) 7 (25.0) 6 (22.1) |
1 (20.0) 0 (0) 4 (80.0) |
0.003 |
| Neurological symptoms No Yes |
25 (15.4) 137 (84.6) |
40 (44.4) 50 (55.6) |
9 (23.7) 29 (76.3) |
24 (88.9) 3 (11.1) |
4 (80.0) 1 (20.0) |
<0.001 |
| Extracranial metastases Yes No |
106 (65.4) 56 (34.6) |
52 (57.8) 38 (42.2) |
28 (73.7) 10 (26.3) |
20 (74.1) 7 (25.9) |
2 (40.0) 3 (60.0) |
0.225 |
| Gene status EGFR mutation ALK rearrangement |
154 (95.1) 8 (4.9) |
82 (91.1) 8 (8.9) |
34 (89.5) 4 (10.5) |
22 (81.5) 5 (18.5) |
3 (60.0) 2 (40.0) |
0.015 |
| Lung-molGPA* 0–2 2.5–4 |
13 (8.0) 149 (92.0) |
11 (12.2) 79 (87.8) |
5 (13.2) 33 (86.8) |
2 (8.0) 25 (92.0) |
2 (40.0) 3 (60.0) |
0.165 |
| First-line chemotherapy EGFR TKIs ALK TKIs PP TP Others |
79 (48.8) 2 (1.2) 72 (44.4) 8 (4.0) 1 (0.6) |
43 (47.8) 2 (2.2) 27 (30.0) 10 (11.1) 8 (4.9) |
21 (55.3) 2 (5.3) 14 (36.8) 1 (2.6) 0 (0) |
15 (55.6) 1 (3.7) 10 (37.0) 0 (0) 1 (3.7) |
/ / / / / |
|
| Brain localized therapy WBRT SRS WBRT+SRS Surgery |
/ / / / |
64 (71.1) 21 (23.3) 5 (5.6) / |
34 (89.4) 2 (5.3) 2 (5.3) / |
/ / / 27 (100.0) |
3 (60.0) 0 (0) 0 (0) 2 (40.0) |
ALK, anaplastic lymphoma kinase; BLT, brain localized treatment; BS, brain surgery; DBR, deferred brain radiotherapy; EBR, early brain radiotherapy; EGFR, epidermal growth factor receptor; GPA, graded prognostic assessment; KPS, Karnofsky performance status; PP, pemetrexed with platinum; SRS, stereotactic radiosurgery; SM, systemic medication; TKI, tyrosine kinase inhibitor; TP, paclitaxel with platinum; WBRT, whole-brain radiotherapy.
*An update of the DS-GPA using molecular markers.